journal
MENU ▼
Read by QxMD icon Read
search

Leukemia & Lymphoma

journal
https://www.readbyqxmd.com/read/27911138/phase-1-dose-escalation-study-of-oral-abexinostat-for-the-treatment-of-patients-with-relapsed-refractory-higher-risk-myelodysplastic-syndromes-acute-myeloid-leukemia-or-acute-lymphoblastic-leukemia
#1
Norbert Vey, Thomas Prebet, Claire Thalamas, Aude Charbonnier, Jerome Rey, Ioana Kloos, Emily Liu, Ying Luan, Remus Vezan, Thorsten Graef, Christian Recher
Histone deacetylase (HDAC) inhibitor abexinostat is under investigation for the treatment of various cancers. Epigenetic changes including aberrant HDAC activity are associated with cancers, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL). In this phase 1 dose-escalation study, 17 patients with relapsed/refractory higher-risk MDS, AML, or ALL received oral abexinostat (60, 80 [starting dose], 100, or 120 mg) twice daily (bid) on Days 1-14 of 21-day cycles...
December 2, 2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27911132/a-new-acute-myeloid-leukemia-case-with-stat5b-rara-gene-fusion-due-to-17q21-2-interstitial-deletion
#2
Chiara Pessina, Claudia Basilico, Angelo Genoni, Emanuela Meroni, Lorenzo Elli, Paola Granata, Rossana Righi, Francesco Pallotti, Barbara Mora, Andrea Ferrario, Francesco Passamonti, Rosario Casalone
No abstract text is available yet for this article.
December 2, 2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27911124/the-impact-of-interferon-alpha2-on-hla-genes-in-patients-with-polycythemia-vera-and-related-neoplasms
#3
Vibe Skov, Caroline Hasselbalch Riley, Mads Thomassen, Lasse Kjær, Thomas Stauffer Larsen, Ole Weis Bjerrum, Torben A Kruse, Hans Carl Hasselbalch
Gene expression profiling in Philadelphia-negative chronic myeloproliferative neoplasms (MPNs) have unraveled significant deregulation of several immune and inflammation genes of potential importance for clonal evolution. Other mechanisms might be downregulation of major histocompatibility class I and II genes used by tumor cells to escape antitumor T-cell-mediated immune responses. Several genes encoding human leukocyte antigen (HLA) class I and II molecules have been shown to be significantly downregulated...
December 2, 2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27908226/high-coincidence-of-chronic-lymphocytic-leukemia-and-myeloproliferative-neoplasms-detection-bias-or-a-clue-to-a-common-pathophysiological-path
#4
Claire van de Ree-Pellikaan, Lina van der Straten, Jurgen A Riedl, Mark-David Levin, Peter E Westerweel
No abstract text is available yet for this article.
December 2, 2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27908223/proteomic-profiling-in-plasma-cell-disorders-a-feasibility-study
#5
Sham Mailankody, Sean M Devlin, Neha Korde, Nikoletta Lendvai, Alexander Lesokhin, Heather Landau, Hani Hassoun, Andrea Ballagi, Daniel Ekman, David J Chung, Minal Patel, Guenther Koehne, Sergio Giralt, Ola Landgren
No abstract text is available yet for this article.
December 2, 2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27899039/sensitive-monitoring-of-acute-promyelocytic-leukemia-by-pml-rara-dna-q-pcr
#6
Ivar O Kommers, Paul A Bartley, Bradley Budgen, Sue Latham, Ashanka Beligaswatte, Shane G Supple, Alberto Catalano, Harry J Iland, Alexander A Morley, David M Ross
No abstract text is available yet for this article.
November 30, 2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27897450/vascular-endothelial-growth-factor-overexpression-in-myelodysplastic-syndrome-bone-marrow-cells-biological-and-clinical-implications
#7
Rosangela Invernizzi, Erica Travaglino, Matteo Giovanni Della Porta, Luca Malcovati, Anna Gallì, Raffaella Bastia, Mariella Ciola, Ilaria Ambaglio, Emanuela Boveri, Vittorio Rosti, Mario Cazzola
In myelodysplastic syndrome (MDS), vascular endothelial growth factor (VEGF) may have regulatory effects on the hematopoietic system and contribute to disease progression. We analyzed by immunocytochemistry VEGF expression in bone marrow (BM) cells from 188 patients with MDS and 96 non-hemopathic subjects. We also measured VEGF BM plasma levels and in vitro VEGF release. Our aims were to evaluate whether VEGF expression abnormalities were associated with relevant laboratory or clinical findings and their possible prognostic value...
November 29, 2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27894215/the-molecular-pathogenesis-of-mantle-cell-lymphoma
#8
Niklas Vogt, Beiying Dai, Tabea Erdmann, Wolfgang E Berdel, Georg Lenz
Mantle cell lymphoma (MCL) is characterized by the translocation t(11;14) leading to constitutive cyclin D1 overexpression. However, overexpression of cyclin D1 alone is insufficient to cause malignant transformation. Secondary genetic alterations and deregulated signaling pathways involved in DNA damage response, cell proliferation, and apoptosis are indispensable for MCL lymphomagenesis. Recent studies investigating the biology of MCL have revealed crucial importance of B-cell receptor (BCR), nuclear factor-kappa B (NF-κB), phosphoinositide 3-kinase (PI3K), and BCL2 signaling for the molecular pathogenesis of MCL...
November 28, 2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27894207/when-to-recommend-a-second-autograft-in-patients-with-relapsed-myeloma
#9
Dimitrios C Ziogas, Evangelos Terpos, Meletios A Dimopoulos
In the current evolving landscape of myeloma therapies, no recommended salvage strategy exists for patients with relapsed multiple myeloma (MM) after initial successful autologous stem cell transplantation (ASCT) and therapeutic options extend from conventional chemotherapy and novel agents to second autologous and allogeneic transplants. In this article, we summarize the documented evidence about the utilization of second ASCT in patients with relapsed MM after a primary auto-graft and discuss the correct timing for such a salvage approach, the individual characteristics of patients who will benefit more, as well as the therapeutic role of second ASCT in the modern era of forthcoming anti-myeloma treatments...
November 28, 2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27894205/outcomes-of-second-line-treatment-in-chronic-lymphocytic-leukemia-a-population-based-study-from-a-well-defined-geographical-region-between-2003-and-2013
#10
Anna Asklid, Maria Winqvist, Sandra Eketorp Sylvan, Agnes Mattsson, Einar Björgvinsson, Frans Søltoft, Johanna Repits, Joris Diels, Anders Österborg, Lotta Hansson
No abstract text is available yet for this article.
November 28, 2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27894199/socio-economic-risk-patterns-in-hodgkin-lymphoma-not-more-but-new-studies-are-warranted
#11
Henrik Hjalgrim, Klaus Rostgaard
No abstract text is available yet for this article.
November 28, 2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27892750/risk-of-hepatitis-b-reactivation-under-treatment-with-tyrosine-kinase-inhibitors-for-chronic-myeloid-leukemia
#12
Ester Maria Orlandi, Chiara Elena, Elisa Bono
No abstract text is available yet for this article.
November 28, 2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27892749/high-non-relapse-mortality-and-low-relapse-incidence-in-gender-mismatched-allogeneic-hematopoietic-stem-cell-transplantation-from-a-parous-female-donor-with-a-male-child
#13
Akihito Shinohara, Yoshihiro Inamoto, Saiko Kurosawa, Nobuhiro Hiramoto, Ryosuke Ueda, Takashi Tanaka, Kohei Tada, Yujin Kobayashi, Noriyuki Morikawa, Keiji Okinaka, Sung-Won Kim, Kinuko Tajima, Takahiro Fukuda
To clarify the influence of exposure to a male fetus during a female donor's (FD) pregnancy in allogeneic hematopoietic stem cell transplantation (HSCT), we retrospectively examined 292 HSCT patients. The 5-year non-relapse mortality (NRM) was 33.5% among 31 male recipients who had HSCT from FD with a male child (MC), 23.0% among 40 male recipients who had HSCT from FD without MC and 19.6% among 221 other recipients. The 5-year relapse incidence (RI) was 22.6%, 42.0%, and 43.1% for the respective group. In multivariate analysis, male recipients who had HSCT from FD with MC had an increased risk of NRM (hazard ratio [HR] 1...
November 28, 2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27892747/blunt-tools-burning-questions-using-cancer-registry-data-to-study-relapsed-refractory-lymphoma
#14
Adam J Olszewski
No abstract text is available yet for this article.
November 28, 2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27892745/gene-expression-based-monocyte-specific-clustering-of-acute-myeloid-leukemias-reveals-novel-associations
#15
Sofieke Elisabeth Klamer, Benjamin Nota, Michael Moorhouse, Carlijn Voermans, C Ellen van der Schoot
No abstract text is available yet for this article.
November 28, 2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27892742/a-common-ancestral-dnmt3a-mutated-preleukemic-clone-giving-rise-to-aml-and-mds-in-an-adolescent-girl
#16
Gudrun Göhring, Kathrin Thomay, Gunnar Schmidt, Tim Ripperger, Michael Xu, Nicole Wittner, Mwe Mwe Chao, Irith Baumann, Marena Niewisch, Dirk Reinhardt, Thomas Klingebiel, Felicitas Thol, Brigitte Schlegelberger, Charlotte M Niemeyer
No abstract text is available yet for this article.
November 28, 2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27885886/arial-fibrillation-in-patients-with-chronic-lymphocytic-leukemia-cll
#17
Tait D Shanafelt, Sameer A Parikh, Peter A Noseworthy, Valentin Goede, Kari G Chaffee, Jasmin Bahlo, Timothy G Call, Susan M Schwager, Wei Ding, Barbara Eichhorst, Kirsten Fischer, Jose F Leis, Asher Alban Chanan-Khan, Michael Hallek, Susan L Slager, Neil E Kay
Although preliminary data suggests that ibrutinib may increase risk of atrial fibrillation (AF), the incidence of AF in a general cohort of chronic lymphocytic leukemia (CLL) patients is unknown. We evaluated the prevalence of AF at CLL diagnosis and incidence of AF during follow-up in 2444 patients with newly diagnosed CLL. A prior history of AF was present at CLL diagnosis in 148 (6.1%). Among the 2292 patients without history of AF, 139 (6.1%) developed incident AF during follow-up (incidence approximately 1%/year)...
November 25, 2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27881052/prognostic-value-of-lactate-dehydrogenase-in-chinese-patients-with-newly-diagnosed-transplant-eligible-multiple-myeloma
#18
Beihui Huang, Jin Lu, Xiaotao Wang, Yang Xiao, Ying Zhao, Hongming Huang, Junru Liu, Meilan Chen, Jingli Gu, Shiwen Yuan, Dong Zheng, Yonghua Li, Xiaojun Huang, Juan Li
No abstract text is available yet for this article.
November 23, 2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27881041/incidence-and-survival-outcomes-of-chronic-myelomonocytic-leukemia-in-the-united-states
#19
Guru Subramanian Guru Murthy, Ishwori Dhakal, Paulette Mehta
Chronic myelomonocytic leukemia (CMML) is an aggressive neoplasm with sparse data on outcomes at a population level. Using Surveillance Epidemiology and End Results (SEER) database, we identified 2238 patients with CMML diagnosed in the period 2003-2013. We found that the disease incidence was significantly higher with advancing age and lower in females, Blacks, and Asian/pacific islanders. Median OS declined significantly with increasing age (age 20-39 - 25 months, age 40-59 - 20 months, age 60-79 - 18 months, and age ≥80 - 11 months, p < ...
November 23, 2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27881039/fludarabine-cyclophosphamide-and-lenalidomide-in-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-a-multicenter-phase-i-ii-gimema-trial
#20
Francesca R Mauro, Angelo M Carella, Stefano Molica, Francesca Paoloni, Anna M Liberati, Francesco Zaja, Valeria Belsito, Agostino Cortellezzi, Rita Rizzi, Patrizia Tosi, Mauro Spriano, Antonietta Ferretti, Mauro Nanni, Marilisa Marinelli, Maria S De Propris, Sonia M Orlando, Marco Vignetti, Antonio Cuneo, Anna R Guarini, Robin Foà
The activity and safety of a regimen combining lenalidomide with fludarabine and cyclophosphamide (FC) was investigated in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Treatment consisted of six monthly courses of the FC regimen combined with 14 days of lenalidomide given at the starting dose of 2.5 mg during course 1. The maximum tolerated dose of lenalidomide was 5 mg. Forty patients were assessed for response, 66% were IGHV unmutated, 45% showed deletion 11q or 17p. The overall response and complete remission rates were 62...
November 23, 2016: Leukemia & Lymphoma
journal
journal
30440
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"